TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Prototype for Simulation for Environmental Exposure Education (SE3)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* In middle school.~* Ability to use a mobile tablet.~* Have access to wifi in location of intervention implementation.~* Reside in the geographic areas of implementation: California, Michigan, Florida~Exclusion Criteria:~* Age not within middle school range.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 13 Years
- Healthy Volunteers: t

Study Arms:
- Single Arm, Intervention with SE3 Game (Type: EXPERIMENTAL): This is a single arm study. This arm will receive the intervention. This intervention is a prototype of online game, about 50 minutes in duration. The online game provides gameplay that allows the user, with a gameplay narrative, to identify and remove sources of environmental hazards in the home environment. Participants play the prototype game for about 50 minutes at which time the intervention is complete.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Taking Choline Supplements During Pregnancy for Improving Infant Brain Development

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant~* Between 10 and 18 weeks gestational age~* Healthy~* Diagnosis of psychosis~Exclusion Criteria:~* Use of any tobacco or nicotine product~* Drinks more than 1 alcoholic drink per day~* Use of illicit drugs~* History of trimethylaminuria~* History of kidney disease~* History of liver disease~* History of pre-pregnancy diabetes~* History of Parkinson's disease~* History of fetal death, fetal/infant congenital malformation, or fetal/infant genetic abnormality~* Evidence of noncompliance to study medication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Participants will take placebo
- 2 (Type: ACTIVE_COMPARATOR): Participants will take choline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Patients must have the below proven, probable or possible deep mycosis;~  1. invasive aspergillosis~ 2. chronic pulmonary aspergillosis~ 3. mucormycosis~ 4. cryptococcosis~* Female patients must be non-lactating and at no risk for pregnancy.~Main Exclusion Criteria:~* Women who are pregnant or breastfeeding.~* Patients with hypersensitivity to any of the components of the azole class of antifungals or the investigational product.~* Patients at high risk for QT/QTc prolongation, or patients with risk factors for torsades de pointes, or taking concomitant medications known to prolong the QT/QTc interval.~* Patients with a history of short QT syndrome.~* Patients with liver dysfunction at enrollment.~* Patients with moderate to severe kidney dysfunction at enrollment.~* Patients who receive prohibited concomitant drugs.~* Patients with any other fungal infection other than Aspergillus species, order Mucorales, or Cryptococcus species.~* Patients who are not expected to survive study duration.~* Patients with an underlying disease, complication or general condition that would complicate safety and efficacy evaluations.~* Patients with a history of taking voriconazole for deep mycosis and showing no response to this treatment.~* Patients taking systemic antifungals who are unable to stop taking these drugs during the study, or who are showing signs of improvement in their symptoms of deep mycosis as a result of these drugs.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AK1820 (Type: EXPERIMENTAL): Participants will receive a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) or orally for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they will reach a treatment endpoint or for a maximum of 84 days.
- Voriconazole (Type: ACTIVE_COMPARATOR): Participants will receive a loading dose of voriconazole, 6 mg/kg every 12 hours IV or 300 mg every 12 hours orally for the first 24 hours, followed by a maintenance dose from Day 2 of 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they will reach a treatment endpoint or for a maximum of 84 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Using Preoperative Anxiety Score to Determine the Precise Dose of Butorphanol for Sedation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ASA Ⅰ-Ⅱ~* age 18-75 years~* surgical operation of lower extremities in orthopedics~* no contraindication of epidural anesthesia~Exclusion Criteria:~* with central system disease~* with cardiovascular disease~* with autonomic nervous system disease~* long term use of analgesic drugs ,sedative drugs,and anti-anxiety drugs~* language barrier~* unwilling to cooperate with the experimenter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- High anxiety butorphanol group (Type: EXPERIMENTAL): preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety butorphanol group were \>10，and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
- High anxiety 0.9% saline group (Type: PLACEBO_COMPARATOR): preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in high anxiety 0.9% saline group were \>10, and received an infusion of the same volume of 0.9% saline
- Low anxiety butorphanol group (Type: EXPERIMENTAL): preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety butorphanol group were ≤10,and received an intravenous loading dose of 15ug/kg butorphanol 5 mins before starting the surgery, then followed by infusion of 7.5ug/kg/h butorphanol and stopped infusion when the Ramsay sedation score (RSS) reached 4
- Low anxiety 0.9% saline group (Type: PLACEBO_COMPARATOR): preoperative anxiety score of Amsterdam pre-operative anxiety and information scale(APAIS) in low anxiety 0.9% saline group were ≤10, and received an infusion of the same volume of 0.9% saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Infants of 6 weeks of age (-7 to + 7 days) on date of enrollment.~2. Healthy, as assessed from medical history and physical examination by a study physician,~3. Written informed consent obtained from parents or legal representatives who have been properly informed about the study and are able to comply with planned study procedures.~Exclusion Criteria:~1. Vaccinated with any poliovirus vaccine prior to inclusion,~2. A household contact with OPV vaccination history in the past 4 weeks,~3. HIV infection or pharmacologic immunosuppression,~4. Known allergy to any component of the study vaccines (phenoxyethanol, formaldehyde),~5. Uncontrolled coagulopathy or blood disorder contraindicating intramuscular and intradermal injections,~6. Acute severe febrile illness on day of vaccination deemed by the Investigator(s) to be a contraindication for vaccination,~7. Not suitable for inclusion or is unlikely to comply with the protocol in the opinion of the investigator(s).

- Gender: ALL
- Minimum Age: 5 Weeks
- Maximum Age: 7 Weeks
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): 3 doses IPV IM at 10, 14 \& 36 weeks of age incl. blood sampling at 10, 14, 18 \& 40 weeks.
- Group B (Type: EXPERIMENTAL): 2 doses IPV IM at 14 \& 36 weeks of age incl. blood sampling at 14, 18, 36 \& 40 weeks.
- Group C (Type: EXPERIMENTAL): 3 doses f-IPV ID at 10, 14 \& 36 weeks of age incl. blood sampling at 10, 14, 18 \& 40 weeks.
- Group D (Type: EXPERIMENTAL): 2 doses f-IPV ID at 14 \& 36 weeks of age incl. blood sampling at 14, 18, 36 \& 40 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Reactivation of chronic hepatitis B characterized by rise in ALT level \>5 times upper limit of normal along with HBV DNA level \>105 copies/ml (\~1.8x104 IU/ml) presenting as ACLF~* Acute hepatic insult~* Jaundice (bilirubin ≥5 mg/dL) and coagulopathy (INR\>1.5)~* Complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease.~Exclusion Criteria:~* Superinfection with other viruses (Hepatitis E, A, D and C)~* Coexistent hepatocellular carcinoma (HCC)~* Portal vein thrombosis~* Coexistent renal impairment~* Pregnancy~* Co-infection with HIV infection or Patients received previous course of any antiviral~* Immunomodulator or cytotoxic/immunosuppressive therapy for chronic hepatitis or other illness within at least the preceding 12 month.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: NO_INTERVENTION): Placebo was the multivitamin capsule which was similar in appearance as of Tenofovir disoproxil fumarate and was given once a day till 3 month.
- Tenofovir disoproxil fumarate (TDF) (Type: ACTIVE_COMPARATOR): Tenofovir disoproxil fumarate (TDF) is a potent, rapidly acting, oral acyclic nucleotide analogue, reverse transcriptase inhibitor that has been shown to be highly effective in suppressing hepatitis B virus replication. Tenofovir has also shown excellent activity against HBV in both LAM- naïve and LAM-resistant patients. Its efficacy has not been evaluated in patients of reactivation of hepatitis B who present as ACLF

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* healthy men or women,~* age 18 to 45 years inclusive;~* normal medical history and physical examination; and~* no clinically significant abnormalities from:~* urine dipstick for glucose, protein, and blood~* complete blood count,~* serum hepatic transaminases,~* total bilirubin (direct if abnormal),~* creatinine,~* electrolytes,~* albumin, or~* electrocardiogram.~* Women must have a negative pregnancy test.~Exclusion Criteria:~* travel to a cholera endemic area in the previous 5 years;~* abnormal stool pattern or regular use of laxatives;~* history of eating disorders (such as bulimia), anal or rectal disorders, allergy to tetracycline and/or ciprofloxacin;~* history of cholera or enterotoxigenic E. coli challenge or infection;~* current or recent antibiotic use;~* pregnancy or nursing;~* positive serology for HIV, hepatitis B antigen, or hepatitis C;~* any immunosuppressive medical condition;~* history of hospitalization for psychiatric illness or use of specific psychiatric drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PXVX0200 (Type: EXPERIMENTAL): Biological: PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 5x10\^8 CFU
- Placebo (Type: PLACEBO_COMPARATOR): Biological: Placebo physiological saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have given a written, informed consent.~2. Be able and willing to follow instructions, including participation in study assessments, and be present for the required study visits for the duration of the study.~3. Have a best corrected visual acuity.~4. Have a patient-reported history of dry eye in both eyes.~5. Use and/or desire to use an artificial tear substitute for dry eye symptoms within the past 6 months.~6. A negative urine pregnancy test if female of childbearing potential.~7. Have a corneal fluorescein staining score of ≥ 2 in any corneal surface segment in at least one eye at Visit 1.~   -~Exclusion Criteria:~1. Have contraindications to the use of the study drug.~2. Have known allergy or sensitivity to the study drug or components thereof.~3. Have anterior blepharitis.~4. Be diagnosed with an on-going ocular infection or active ocular inflammation.~5. Use contact lenses within 1 week before Visit 1 or during the course of the study.~6. Have previously had Laser-Assisted in Situ Keratomileusis (LASIK) surgery within 12 months prior to Visit 1.~7. Be currently taking any topical ophthalmic prescription or over-the-counter (OTC) solutions, artificial tears, gels, or scrubs and cannot discontinue these medications for the duration of the trial.~8. Have used topical ocular cyclosporine within 30 days prior to Visit 1.~9. Have had a past or present evidence of malignancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Thymosin Beta 4 (Type: ACTIVE_COMPARATOR): RGN-259 is a preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4
- Placebo (Type: PLACEBO_COMPARATOR): The placebo solution is composed of the same excipients as RGN-259 but does not contain Tβ4. The Placebo is identical to the RGN-259 eye drops in color, consistency, and odor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients with Juvenile idiopathic arthritis who are not responding well to conventional therapy and receive Humira will be enrolled in the survey~Exclusion Criteria:~* Contraindications according to the Package Insert~* Patients who have serious infections~* Patients who have tuberculosis~* Patients with a history of hypersensitivity to any ingredient of Humira~* Patients who have demyelinating disease or with a history of demyelinating disease~* Patients who have congestive cardiac failure

- Gender: ALL
- Minimum Age: None
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Humira (Type: None): Participants with juvenile idiopathic arthritis who received Humira (adalimumab).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (over 18)~* Suffering from atopic eczema with symptoms of redness, dry skin, scaling and/or itchiness on hands or arms~* Otherwise healthy~* Able to provide informed consent~Exclusion Criteria:~* Active allergic skin responses~* Unstable or serious illness (eg kidney, liver, GIT, heart conditions, diabetes, mood disorders, cancer)~* Use of immunosuppressive medication within the last 3 months~* Pregnant or lactating women~* Smokers~* Chronic past and/or current alcohol use (\>14 alcoholic drinks week)~* Allergic to any of the ingredients in active or comparator formula~  * An unstable illness is any illness that is currently not being treated with a stable dose of medication or is fluctuating in severity. A serious illness is a condition that carries a risk of mortality, negatively impacts quality of life and daily function and/or is burdensome in symptoms and/or treatments.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.5% Palmitoylethanolamide (PEA) sold as Levagen+ (Type: EXPERIMENTAL): Investigational product will be provided as a topical cream containing 1.5% PEA and participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.
- Placebo comparator (Type: PLACEBO_COMPARATOR): A comparator placebo moisturiser cream (an unscented moisturizing base cream) will be provided and applied in the same manner as the active ingredient group. Participants will be asked to apply to their affected site 2 times daily for 4 weeks. Cream should be applied liberally (as you would a moisturiser cream) such to coat the affected area and absorb into the skin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern cooperative oncology group performance status (ECOG PS) score: 0-1 points~* Pathological diagnosis of oral squamous cell carcinoma (including tongue, gums, cheeks, mouth floor, hard palate, posterior molar region)~* Clinical stage of III/IVA (AJCC 2018)~* Blood routine: white blood cells \> 3,000/mm3, hemoglobin \> 8g/L, platelets \> 80,000/mm3~* Liver function: Alanine Transaminase/Aspartate Transaminase \<2.5 times the upper limit of normal, bilirubin \<1.5 times the upper limit of normal~* Renal function: serum creatinine \<1.5 times the upper limit of normal~* Sign the informed consent~Exclusion Criteria:~* There are still unresolved toxic reactions above CTCAE level 2 caused by previous anti-cancer treatment~* Grade 3-4 allergic reactions to Toripalimab, paclitaxcel or cisplatin~* Active severe clinical infection (\> CTCAE 5.0 version 2 infection)~* Difficult to control hypertension or cardiovascular disease with clinical significance (such as activity)-such as cerebrovascular accident (\< 6 months before treatment), myocardial infarction (\< 6 months before treatment), unstable angina, New York Cardiology Society (NYHA Appendix 5) congestive heart failure grade II or above, or severe arrhythmia that cannot be controlled with drugs or has potential impact on experimental treatment~* Chronic diseases requiring immunotherapy or hormone therapy~* Women during pregnancy or lactation~* Participated in other clinical studies within 30 days before enrollment~* Other circumstances that the investigator thinks are not suitable for participating in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant therapy with Toripalimab, Paclitaxcel and Cisplatin (Type: EXPERIMENTAL): Pre-operative neoadjuvant therapy will be used with the combination of immune checkpoint inhibitor of Toripalimab, and chemotherapy agents of paclitaxcel and cisplatin in patients with locally advanced OSCC. After inductive therapy, the patients will receive radical surgery and post-operative radiotherapy/chemoradiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete